Merck licenses a KRAS G12D inhibitor for $400M upfront
Back in 2023, entrepreneur and synthetic chemist Tao Hu sold a KRAS G12D inhibitor to AstraZeneca. Today, he's selling another KRAS G12D inhibitor, this time to Merck — but with a twist that could make it ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.